Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antihormone Therapy in Recurrent Metastatic Breast Cancer—Reply

Antihormone Therapy in Recurrent Metastatic Breast Cancer—Reply In Reply: Dr Pritchard is correct: a person with hormone receptor–positive breast cancer would likely receive antihormone therapy for recurrent metastatic disease and would remain on a given agent if tolerated until the disease worsened or recurred. For Ms H, that would have meant starting tamoxifen or an aromatase inhibitor at the first recurrence and then switching to the other when disease worsened. Although the authors of the article were provided with detailed information on Ms H's radiation and surgical therapies, we do not know whether she received antihormone therapies. Back to top Article Information Financial Disclosures: Dr Abrahm reported that she is a member of the speakers' bureau for Merck and Purdue Pharma and is on the advisory board for Endo Pharmaceuticals and Wyeth. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Antihormone Therapy in Recurrent Metastatic Breast Cancer—Reply

JAMA , Volume 299 (23) – Jun 18, 2008

Antihormone Therapy in Recurrent Metastatic Breast Cancer—Reply

Abstract

In Reply: Dr Pritchard is correct: a person with hormone receptor–positive breast cancer would likely receive antihormone therapy for recurrent metastatic disease and would remain on a given agent if tolerated until the disease worsened or recurred. For Ms H, that would have meant starting tamoxifen or an aromatase inhibitor at the first recurrence and then switching to the other when disease worsened. Although the authors of the article were provided with detailed information on Ms...
Loading next page...
 
/lp/american-medical-association/antihormone-therapy-in-recurrent-metastatic-breast-cancer-reply-bs6kPS0zHi
Publisher
American Medical Association
Copyright
Copyright © 2008 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.299.23.2745-b
Publisher site
See Article on Publisher Site

Abstract

In Reply: Dr Pritchard is correct: a person with hormone receptor–positive breast cancer would likely receive antihormone therapy for recurrent metastatic disease and would remain on a given agent if tolerated until the disease worsened or recurred. For Ms H, that would have meant starting tamoxifen or an aromatase inhibitor at the first recurrence and then switching to the other when disease worsened. Although the authors of the article were provided with detailed information on Ms H's radiation and surgical therapies, we do not know whether she received antihormone therapies. Back to top Article Information Financial Disclosures: Dr Abrahm reported that she is a member of the speakers' bureau for Merck and Purdue Pharma and is on the advisory board for Endo Pharmaceuticals and Wyeth.

Journal

JAMAAmerican Medical Association

Published: Jun 18, 2008

There are no references for this article.